Opinion|Videos|October 13, 2023

Updates in the Management of Lower-Risk MDS

Author(s)Amer Zeidan, MBBS

Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.

Episodes in this series

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 1 Overview of Myelodysplastic Syndrome

Elias Jabbour, MD, an expert on myelodysplastic syndrome

EP. 2 Clinical Insights on Treating Myelodysplastic Syndrome

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 3 IMerge Trial: Key Efficacy Outcomes

Abdulraheem Yacoub, MD, an expert on myelodysplastic syndrome

EP. 4 Data Updates From the IMerge Trial

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 5 Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS

Eytan M. Stein, MD, an expert on myelodysplastic syndrome

EP. 6 Evolving Treatment Landscape in Lower-Risk MDS

EP. 7 Safety Outcomes for Imetelstat in Lower-Risk MDS

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 8 Updates in the Management of Lower-Risk MDS

Amer Zeidan, MBBS, MHS, an expert on myelodysplastic syndrome

EP. 9 Recent Updates in Lower-Risk MDS

Yazan Madanat, MD, an expert on myelodysplastic syndromes

EP. 10 Updates in Lower-Risk MDS: Imetelstat

Yazan Madanat, MD, an expert on MDS

EP. 11 Key Updates in Lower-Risk MDS

Related Content

Exploring Strategies in ESA-Refractory Lower-Risk MDS

ByTargeted Oncology Staff

March 9th 2026

Addressing Second-Line Approaches in Low-Risk MDS

ByTargeted Oncology Staff

February 25th 2026

Less Than 5% of Older Adults Joined Blood Cancer Trials, Study Shows

ByAndrea Eleazar, MHS,Inna Gong, MD, PhD

February 10th 2026

CAR T in Heme Malignancies: Patient Outcomes Inform Care Needs

ByAndrea Eleazar, MHS

January 7th 2026

The Top 5 Blood Cancer Advancements in 2025

December 27th 2025

Latest CME

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Wyoming State Oncology Society

Wyoming State Oncology Society

1 Session is Available!

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD; Benjamin Falit, MD; Jami Fukui, MD; Laura Huppert, MD; Sara A. Hurvitz, MD, FACP; Jodi Kagihara, MD; Irene Kang, MD; William Loui, MD, FACP; Ashley Marumoto, MD; Rebecca Shatsky, MD; Naoko Takebe, MD, PhD; Melinda Telli, MD, FASCO; Rachel Thelen, FNP-C, AOCNP; Teruo Yamauchi, MD, MS

43rd Annual Miami Breast Cancer Conference®

43rd Annual Miami Breast Cancer Conference®

Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

2 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

1 Session is Available!

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Indiana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Indiana

Neil M. Iyengar, MD; Ruta D. Rao, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Kentucky

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Kentucky

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Arkansas

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Arkansas

Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Seth A. Wander, MD, PhD; Girish Kunapareddy, MD

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Iowa

Virginia Kaklamani, MD, DSc; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology Society

Seth A. Wander, MD, PhD; Kit Lu, MD

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

In-Person Event

Immune Therapies in Practice in 2026: Cellular Therapies, ADCs, Bispecifics, and Beyond

May 22, 2026

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Go to PER in Chicago

In-Person + Virtual Event

Go to PER in Chicago

May 29-30, 2026

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD